Adaptations of energy metabolism during cerebellar neurogenesis are co-opted in medulloblastoma

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 268-272

  Tech, Katherine ^a,b   Deshmukh, Mohanish ^b   Gershon, Timothy R ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aerobic glycolysis; Cerebellar development; Hexokinase 2; Medulloblastoma; PkM2; Postnatal neurogenesis

Indexed keywords

HEXOKINASE; HEXOKINASE 2; LACTIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRUVATE KINASE; PYRUVATE KINASE M2; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; LIPID; NMI PROTEIN, HUMAN; SHH PROTEIN, HUMAN; SIGNAL PEPTIDE; SONIC HEDGEHOG PROTEIN;

ADAPTATION; AEROBIC METABOLISM; BRAIN CANCER; CANCER CELL; CELL METABOLISM; CELL PROLIFERATION; CEREBELLAR NEUROGENESIS; CEREBELLUM; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; LIPOGENESIS; MEDULLOBLASTOMA; METABOLIC TRANSFORMATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; ONCOGENE; ONCOGENE C MYB; PROTEIN EXPRESSION; SHORT SURVEY; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; BRAIN; CEREBELLUM TUMOR; GENETICS; LIPID METABOLISM; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CEREBRUM; E2F TRANSCRIPTION FACTORS; ENERGY METABOLISM; GLYCOLYSIS; HEDGEHOG PROTEINS; HEXOKINASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; LIPIDS; LIPOGENESIS; MEDULLOBLASTOMA; MICE; NEUROGENESIS; PPAR GAMMA; PYRUVATE KINASE;

EID: 84920147180     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.017     Document Type: Review

References (48)

1. Hanahan D., Robert A. Weinberg, hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
2. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 2009, 100(9):1369-1372.
3. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews. Cancer 2007, 7(10):763-777.
4. Abramson H.N. The lipogenesis pathway as a cancer target. J. Med. Chem. 2011, 54(16):5615-5638.
5. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033.
6. Dang C.V. Links between metabolism and cancer. Genes Develop. 2012, 26(9):877-890.
7. Bhatia B., et al. Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma. Oncogene 2011, 30(4):410-422.
8. Bhatia B., et al. Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathol. 2012, 123(4):587-600.
9. Gershon T.R., et al. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab. 2013, 1.
10. Yang H., et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 2012, 18(20):5562-5571.
11. Dang L., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465(7300):966.
12. Xu W., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19(1):17-30.
13. Grimmer M.R., Weiss W.A. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediat. 2006, 18(6):634-638.
14. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron 1999, 22(1):103-114.
15. Zurawel R.H., et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes, Chromosomes Cancer 2000, 27(1):44-51.
16. Zurawel R.H., et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000, 28(1):77-81.
17. Hallahan A.R., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004, 64(21):7794-7800.
18. Oliver T.G., et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005, 132(10):2425-2439.
19. 18F]Fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery 2004, 55(6):1280-1289.
20. Tripathi M., et al. Demonstration of diffuse leptomeningeal metastasis in a treated case of medulloblastoma with F-18 FDG PET/CT. Clin. Nucl. Med. 2009, 34(8):530-532.
21. Gershon T., Crowther A.J., Liu H., Miller C.R., Deshmukh M. Cerebellar granule neuron progenitors are the source of Hk2 in the postnatal cerebellum. Cancer Metab. 2013, 1(15).
22. Schüller U., et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form shh-induced medulloblastoma. Cancer Cell 2008, 14(2):123-134.
23. Mao J., et al. A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. Cancer Res. 2006, 66(20):10171-10178.
24. Wolf A., et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med. 2011.
25. Patra K.C., et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013, 24(2):213-228.
26. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144(12):5179-5183.
27. Ruderman N.B., Saha A.K., Kraegen E.W. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003, 144(12):5166-5171.
28. Foster D.W. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J. Clin. Invest. 2012, 122(6):1958-1959.
29. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452(7184):230-233.
30. Eigenbrodt E., et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncogen. 1992, 3(1-2):91-115.
31. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43(7):969-980.
32. Anastasiou D., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 2012, 8(10):839-847.
33. Israelsen W.J., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013, 155(2):397-409.
34. Jones D.T., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488(7409):100-105.
35. Northcott P.A., et al. Subgroup-specific structural variation across 1000 medulloblastoma genomes. Nature 2012, 488(7409):49-56.
36. Kool M., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123(4):473-484.
37. Ellison D.W., et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011, 121(3):381-396.
38. Thompson M.C., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 2006, 24(12):1924-1931.
39. Hitosugi T., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2(97):ra73.
40. Christofk H.R., et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452(7184):181-186.
41. Laurenti E., et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008, 3(6):611-624.
42. Knoepfler P.S., Cheng P.F., Eisenman R.N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Develop. 2002, 16(20):2699-2712.
43. Meyer N., Penn L.Z. Reflecting on 25years with MYC. Nat. Rev. Cancer 2008, 8(12):976-990.
44. Eilers M., Eisenman R.N. Myc,ÄÔs broad reach. Genes Develop. 2008, 22(20):2755-2766.
45. Roussel M.F., Robinson G.W. Role of MYC in Medulloblastoma. Cold Spring Harbor Persp. Med. 2013, 3(11).
46. Miller D.M., et al. C-Myc and cancer metabolism. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 2012, 18(20):5546-5553.
47. Dang C.V. MYC metabolism cell growth and tumorigenesis. Cold SpringHarbor Persp. Med. 2013, 3(8).
48. Zirath H., et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. USA 2013, 110(25):10258-10263.